Healthcare provider profile · identity verified

Jack W. Dyer, M.D.

Family Practice · LUBBOCK, TX · NPI 1730171802

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	252	75
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	221	69
Lisinopril	Lisinopril	213	56
Amlodipine Besylate	Amlodipine Besylate	151	38
Levothyroxine Sodium	Levothyroxine Sodium	132	30
Hydrochlorothiazide	Hydrochlorothiazide	120	33
Losartan Potassium	Losartan Potassium	120	30
Albuterol Sulfate Hfa	Albuterol Sulfate	106	30
Gabapentin	Gabapentin	90	19
Metformin Hcl	Metformin Hcl	80	28
Escitalopram Oxalate	Escitalopram Oxalate	79	19
Rosuvastatin Calcium	Rosuvastatin Calcium	74	16
Fluticasone Propionate	Fluticasone Propionate	69	19
Tamsulosin Hcl	Tamsulosin Hcl	68	19
Citalopram Hbr	Citalopram Hydrobromide	65	13
Omeprazole	Omeprazole	63	13
Pantoprazole Sodium	Pantoprazole Sodium	59	15
Metoprolol Succinate	Metoprolol Succinate	56	14
Glipizide Er	Glipizide	55	suppressed
Paroxetine Hcl	Paroxetine Hcl	55	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	55	suppressed
Alendronate Sodium	Alendronate Sodium	54	12
Bupropion Xl	Bupropion Hcl	54	13
Tramadol Hcl	Tramadol Hcl	52	15
Trazodone Hcl	Trazodone Hcl	51	suppressed
Eliquis	Apixaban	50	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	48	suppressed
Metformin Hcl Er	Metformin Hcl	41	11
Potassium Chloride	Potassium Chloride	40	suppressed
Bupropion Hcl Sr	Bupropion Hcl	39	suppressed
Meloxicam	Meloxicam	35	11
Allopurinol	Allopurinol	34	suppressed
Pravastatin Sodium	Pravastatin Sodium	34	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	suppressed
Montelukast Sodium	Montelukast Sodium	32	suppressed
Alprazolam	Alprazolam	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Famotidine	Famotidine	28	suppressed
Fentanyl	Fentanyl	28	suppressed
Atenolol	Atenolol	27	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Celecoxib	Celecoxib	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Colchicine	Colchicine	22	suppressed
Furosemide	Furosemide	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Desloratadine	Desloratadine	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Ozempic	Semaglutide	17	suppressed
Topiramate	Topiramate	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Estradiol	Estradiol	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Carvedilol	Carvedilol	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Duloxetine Hcl	Duloxetine Hcl	14	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Etodolac	Etodolac	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Torsemide	Torsemide	13	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Verapamil Sr	Verapamil Hcl	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Simvastatin	Simvastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error